$0.03 EPS Expected for Luminex Corporation (LMNX)

October 13, 2017 - By Louis Casey

 $0.03 EPS Expected for Luminex Corporation (LMNX)

Wall Street await Luminex Corporation (NASDAQ:LMNX) to release earnings on October, 30. Analysts forecast earnings per share of $0.03, down exactly $0.03 or 50.00 % from 2014’s $0.06 EPS. The expected LMNX’s profit could reach $1.32 million giving the stock 173.25 P/E in the case that $0.03 earnings per share is reported. After posting $0.20 EPS for the previous quarter, Luminex Corporation’s analysts now forecast -85.00 % negative EPS growth. The stock increased 1.12% or $0.23 during the last trading session, reaching $20.79. About 166,892 shares traded or 12.42% up from the average. Luminex Corporation (NASDAQ:LMNX) has risen 6.31% since October 13, 2016 and is uptrending. It has underperformed by 10.39% the S&P500.

Luminex Corporation (NASDAQ:LMNX) Ratings Coverage

Among 7 analysts covering Luminex Corp (NASDAQ:LMNX), 2 have Buy rating, 1 Sell and 4 Hold. Therefore 29% are positive. Luminex Corp had 11 analyst reports since August 4, 2015 according to SRatingsIntel. The stock of Luminex Corporation (NASDAQ:LMNX) has “Outperform” rating given on Tuesday, August 4 by Wedbush. The stock of Luminex Corporation (NASDAQ:LMNX) earned “Neutral” rating by JP Morgan on Thursday, August 18. The rating was maintained by Piper Jaffray with “Hold” on Sunday, September 17. The firm has “Hold” rating by Jefferies given on Wednesday, September 13. The firm has “Mkt Outperform” rating by Avondale given on Wednesday, October 12. The firm has “Hold” rating given on Friday, June 9 by Jefferies. On Wednesday, August 5 the stock rating was maintained by Jefferies with “Hold”.

Luminex Corporation develops, manufactures and sells biological testing technologies with applications throughout the diagnostics, pharmaceutical and life sciences industries. The company has market cap of $916.24 million. The Company’s products are focused on the molecular diagnostic testing market, which includes human genetics, personalized medicine and infectious disease divisions. It has a 63.36 P/E ratio. The Firm has a range of instruments using its xMAP technology, which includes its LUMINEX 100/200 systems offer 100-plex testing; the Company’s FLEXMAP 3D system is its high-throughput, 500-plex testing system, and its MAGPIX system provides 50-plex testing using imaging rather than flow cytometry.

More news for Luminex Corporation (NASDAQ:LMNX) were recently published by: Prnewswire.com, which released: “Luminex Corporation Declares Third Quarter Cash Dividend” on September 12, 2017. Prnewswire.com‘s article titled: “Luminex Corporation Third Quarter Earnings Release Scheduled for October 30, 2017” and published on October 09, 2017 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Twitter Auto Publish Powered By : XYZScripts.com